Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB)

References

• Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm 1995; 41: 44–8
   Web of Science ®Google Scholar
• Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with poly-sorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997; 14: 325–8
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly-(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target 2001; 9: 209–21
   PubMed Web of Science ®Google Scholar
• Alyautdin RN, Tezikov E, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 1998; 5: 67–74
   Google Scholar
• Ambruosi A, Gelperina S, Khalansky AS, Tanski S, Theisen A, Kreuter J. Influence of surfactants, polymer, and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul 2006; 23: 582–92
   PubMed Web of Science ®Google Scholar
• Begley DJ. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol 1996; 48: 136–46
   PubMed Web of Science ®Google Scholar
• Begley DJ. Delivery of therapeutic agents to the central nervous system: The problems and possibilities. Pharmacol Therap 2004; 104: 29–45
   PubMed Web of Science ®Google Scholar
• Borchard G, Audus KL, Shi F, Kreuter J. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm 1994; 110: 29–35
   Web of Science ®Google Scholar
• Brightman M. Ultrastructure of the brain endothelium. Handbook of experimental pharmacology. physiology and pharmacology of the blood-brain barrier, MWB Bradbury. Springer, Berlin, Heidelberg 1992; 103.: 1–22
   Google Scholar
• Cordon-Cardo C, O’Brien JP, Casals D, Rittmann-Grauer L, Biedler JL, Melamed MR, Bertino JR. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86: 695–8
   PubMed Web of Science ®Google Scholar
• Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 2000; 49: 103–9
   PubMed Web of Science ®Google Scholar
• Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 2002; 126: 131–41
   PubMed Web of Science ®Google Scholar
• Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, Berdiev R, Wohlfart S, Chepurnova N, Kreuter J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. Eur J Pharm Biopharm 2010; 74: 157–63
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GYa, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999; 16: 1564–6
   PubMed Web of Science ®Google Scholar
• Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 2009; 284: 6972–81
   PubMed Web of Science ®Google Scholar
• Hekmatara T, Bernreuther C, Khalansky AS, Theisen A, Weissenberger J, Gelperina S, Kreuter J, Glatzel M. Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects. Clin Neuropathol 2009; 28: 153–64
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate carriers for drug delivery to the brain. Nanoparticles as drug carriers, VP Torchilin. Imperial College Press, London 2006; 527–47
   Google Scholar
• Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 1995; 674: 171–4
   PubMed Web of Science ®Google Scholar
• Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. Covalent attachment of apolipoprotein AI and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Controlled Rel 2007; 118: 54–8
   PubMed Web of Science ®Google Scholar
• Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Controlled Rel 1997; 49: 81–7
   Web of Science ®Google Scholar
• Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ. Direct evidence that polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drugs to nanoparticles. Pharm Res 2003; 20: 409–16
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002; 10: 317–25
   PubMed Web of Science ®Google Scholar
• Kurakhmaeva KB, Djindjikashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS, Kreuter J, Gelperina S, Begley D, Alyautdin RN. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 2009; 17: 564–74
   PubMed Web of Science ®Google Scholar
• Lück M, 1997. Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern. PhD Thesis, Berlin, Freie Universität, pp. 14–24, 137–54
   Google Scholar
• Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K. Covalent linkage of apolipoprotein E to albumin-nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006; 317: 1246–53
   PubMed Web of Science ®Google Scholar
• Nerurkar MM, Burto PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res 1996; 13: 528–34
   PubMed Web of Science ®Google Scholar
• Neuwelt EA, Barnett PA. Blood-brain barrier disruption in the treatment of brain tumors. Animal studies. Implications of the blood-brain barrier and its manipulation, EA Neuwelt. Plenum, New York 1989; 2.: 195–217
   Google Scholar
• Olivier J-C, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 1999; 16: 1836–42
   PubMed Web of Science ®Google Scholar
• Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Kreuter J, Gelperina S. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicol Letters 2008; 178: 9–19
   PubMed Web of Science ®Google Scholar
• Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Langer K, Dreis S, Asmussen B, Kreuter J, Gelperina S. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity. Int. J. Pharm 2007; 337: 346–56
   PubMed Web of Science ®Google Scholar
• Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, Kreuter J, Gelperina S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nano-particles: Revisiting the role of surfactants. J Controlled Rel 2007; 117: 51–8
   PubMed Web of Science ®Google Scholar
• Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, von Briesen H. Polysorbate 80-coating enhances uptake of polybutylcyanoacrylate (PBCA)–nanoparticles by human and bovine primary brain capillary endothelial cells. Europ J Neurosci 2000; 12: 1931–40
   PubMed Web of Science ®Google Scholar
• Sanchez de Juan B, von Briesen H, Gelperina SE, Kreuter J. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. J Drug Target 2006; 14: 614–22
   PubMed Web of Science ®Google Scholar
• Steiniger SCJ, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004; 109: 759–67
   PubMed Web of Science ®Google Scholar
• Tahara K, Kato Y, Yamamoto H, Kreuter J, Kawashima Y. Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells. J Microencapsul 2011; 28: 29–36
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009; 71: 251–6
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: Nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target 2011; 19: 125–32
   PubMed Web of Science ®Google Scholar
• Wagner S, Kufleitner J, Zensi A, Dadparvar M, Wien S, Bungert J, Vogel T, Worek F, Kreuter J, von Briesen H. Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS ONE 2010; 5: e14213
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Bernreuther C, Khalansky AS, Theisen A, Weissenberger J, Gelperina S, Glatzel M, Kreuter J. Increased numbers of injections of doxorubicin bound to nanoparticles lead to enhanced efficacy against rat glioblastoma 101/8. J Nanoneurosci 2009; 1: 144–51
   Google Scholar
• Wohlfart S, Gelperina S, Kreuter J, Transport of drugs across the blood-brain barrier by nanoparticles. J Controlled Rel (e-publ. 2011)
   Google Scholar
• Wohlfart S, Khalansky AS, Bernreuther C, Michaelis M, Cinatl J, Jr., Glatzel M, Kreuter J. Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles. Int J Pharm 2011b; 415: 244–51
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Controlled Rel 2011a; 154: 103–7
   PubMed Web of Science ®Google Scholar
• Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, Glatzel M, Kreuter J. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS ONE 2011c; 6: e19121
   PubMed Web of Science ®Google Scholar
• Woodcock DM, Linsenmeyer ME, Chrojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH. Reversal of multidrug resistance by surfactants. Br J Cancer 1992; 66: 62–8
   PubMed Web of Science ®Google Scholar
• Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Büchel C, Kreuter J. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug Target 2010; 18: 842–8
   PubMed Web of Science ®Google Scholar
• Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Büchel C, von Briesen H, Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Controlled Rel 2009; 137: 78–86
   PubMed Web of Science ®Google Scholar